More good news. BMS appears really serious about getting the combo approved as a standard of care. The question is when. I’ve a feeling the “long pole in the tent” may be bounding toxicity and its mitigation.
Win/win for everybody though. Patients get a very effective combination with durable responses and BMS gets to sell two drugs.
Viewing 3 posts - 1 through 3 (of 3 total)
The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.